Cryptotanshinone inhibits lung tumor growth by increasing CD4+ T cell cytotoxicity through activation of the JAK2/STAT4 pathway

Man,Yonghong; Yang,Le; Zhang,Dongxian; Bi,Yongyi

doi:10.3892/ol.2016.5123

Cryptotanshinone inhibits lung tumor growth by increasing CD4+ T cell cytotoxicity through activation of the JAK2/STAT4 pathway

Authors:
- Yonghong Man
- Le Yang
- Dongxian Zhang
- Yongyi Bi
View Affiliations

Affiliations: School of Public Health, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Basic Medicine, Nanyang Medical College, Nanyang, Henan 473061, P.R. China
Published online on: September 12, 2016 https://doi.org/10.3892/ol.2016.5123
Pages: 4094-4098

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cryptotanshinone is one of the fat‑soluble phenanthrene quinone components. In vitro studies have shown that tanshinone compounds can inhibit the proliferation of various tumor cells and affect cell cycle distribution. The aim of the present study was to better understand the effect of cryptotanshinone on the inhibition of small cell lung cancer by cytotoxic cluster of differentiation (CD)4+ T cells through activation of the Janus kinase 2/signal transducer and activator of transcription 4 (JAK2/STAT4) pathway. The Cell Counting kit‑8 assay and the lactate dehydrogenase assay were used to analyze the cell proliferation of H446 and CD4+ T cells, and the cell cytotoxicity of CD4+ and CD8+ T cells, respectively. JAK2 and STAT4 protein expression was measured by western blot analysis. Cryptotanshinone effectively inhibited the tumor growth of the H446 cells and the cell proliferation of the CD4+ T cells. Treatment with cryptotanshinone increased the cytotoxicity of the CD4+ T cells, but could not affect the cytotoxicity of the CD8+ T cells. Meanwhile, cryptotanshinone induced phosphorylated (p)‑JAK2 and p‑STAT4 protein expression in the CD4+ T cells. These results suggest that cryptotanshinone inhibits the cell growth of lung tumors by increasing CD4+ T cell toxicity through activation of the JAK2/STAT4 pathway.

View Figures

View References

1	Perera Y, Toro ND, Gorovaya L, Fernandez-DE-Cossio J, Farina HG and Perea SE: Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2:935–944. 2014.PubMed/NCBI
2	Huang Y, Li W, Wang CC, Wu X and Zheng J: Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes. Fertil Steril. 102:589–596.e4. 2014. View Article : Google Scholar : PubMed/NCBI
3	Makris N, Edgren M, Mavroidis P and Lind BK: Investigation of the dose- and time-dependence of the induction of different types of cell death in a small cell lung cancer cell line: Implementation of the repairable-conditionally repairable model. Int J Oncol. 42:2019–2027. 2013.PubMed/NCBI
4	Wang F, Xu J, Zhu Q, Qin X, Cao Y, Lou J, Xu Y, Ke X, Li Q, Xie E, et al: Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: A possible mechanism of tumor-induced immunosuppression. PLoS One. 8:e790642013. View Article : Google Scholar : PubMed/NCBI
5	Wang YY, He XY, Cai YY, Wang ZJ and Lu SH: The variation of CD4+CD25+ regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN. Target Oncol. 6:147–154. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wang W, Hodkinson P, McLaren F, MacKinnon A, Wallace W, Howie S and Sethi T: Small cell lung cancer tumour cells induce regulatory T lymphocytes and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer. 131:E928–E937. 2012. View Article : Google Scholar : PubMed/NCBI
7	Yin HQ, Choi YJ, Kim YC, Sohn DH, Ryu SY and Lee BH: Salvia miltiorrhiza Bunge and its active component cryptotanshinone protects primary cultured rat hepatocytes from acute ethanol-induced cytotoxicity and fatty infiltration. Food Chem Toxicol. 47:98–103. 2009. View Article : Google Scholar : PubMed/NCBI
8	Pan Y, Bi HC, Zhong GP, Chen X, Zuo Z, Zhao LZ, Gu LQ, Liu PQ, Huang ZY, Zhou SF and Huang M: Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). Xenobiotica. 38:382–398. 2008. View Article : Google Scholar : PubMed/NCBI
9	Dai H, Wang M, Li X, Wang L, Li Y and Xue M: Structural elucidation of in vitro and in vivo metabolites of cryptotanshinone by HPLC-DAD-ESI-MS(n). J Pharm Biomed Anal. 48:885–896. 2008. View Article : Google Scholar : PubMed/NCBI
10	Cha JD, Lee JH, Choi KM, Choi SM and Park JH: Synergistic effect between cryptotanshinone and antibiotics against clinic methicillin and vancomycin-resistant staphylococcus aureus. Evid Based Complement Alternat Med. 2014:4505722014. View Article : Google Scholar : PubMed/NCBI
11	Tang Y, Chen Y, Chu Z, Yan B and Xu L: Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol. 723:494–500. 2014. View Article : Google Scholar : PubMed/NCBI
12	Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K and Magiera-Molendowska H: Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med. 6:307–311. 2000.PubMed/NCBI
13	Williams M, Liu ZW, Hunter A and Macbeth F: An updated systematic review of lung chemo-radiotherapy using a new evidence aggregation method. Lung Cancer. 87:290–295. 2015. View Article : Google Scholar : PubMed/NCBI
14	Cui X, Jin T, Wang X, Jin G, Li Z and Lin L: NAD(P)H: Quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer. Oncol Rep. 32:2589–2595. 2014.PubMed/NCBI
15	Huang B, Gao Y, Tian D and Zheng M: A small interfering ABCE1-targeting RNA inhibits the proliferation and invasiveness of small cell lung cancer. Int J Mol Med. 25:687–693. 2010.PubMed/NCBI
16	Li S, Wang H, Hong L, Liu W, Huang F, Wang J, Wang P, Zhang X and Zhou J: Cryptotanshinone inhibits breast cancer cell growth by suppressing estrogen receptor signaling. Cancer Biol Ther. 16:176–184. 2015. View Article : Google Scholar : PubMed/NCBI
17	Yu HJ, Park C, Kim SJ, Cho NP and Cho SD: Signal transducer and activators of transcription 3 regulates cryptotanshinone-induced apoptosis in human mucoepidermoid carcinoma cells. Pharmacogn Mag. 10(Suppl 3): S622–S629. 2014.PubMed/NCBI
18	Park IJ, Yang WK, Nam SH, Hong J, Yang KR, Kim J, Kim SS, Choe W, Kang I and Ha J: Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. Apoptosis. 19:615–628. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zikos TA, Donnenberg AD, Landreneau RJ, Luketich JD and Donnenberg VS: Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother. 60:819–827. 2011. View Article : Google Scholar : PubMed/NCBI
20	Que Z, Zou F, Zhang A, Zheng Y, Bi L, Zhong J, Tian J and Liu J: Ganoderic acid Me induces the apoptosis of competent T cells and increases the proportion of Treg cells through enhancing the expression and activation of indoleamine 2,3-dioxygenase in mouse lewis lung cancer cells. Int Immunopharmacol. 23:192–204. 2014. View Article : Google Scholar : PubMed/NCBI
21	Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G, et al: Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 85:81–87. 2014. View Article : Google Scholar : PubMed/NCBI
22	Grzesk E, Koltan S, Debski R, Wysocki M, Gruszka M, Kubicka M, Kołtan A, Grześk G, Manysiak S and Odrowąż-Sypniewska G: Concentrations of IL-15, IL-18, IFN-γ and activity of CD4, CD8 and NK cells at admission in children with viral bronchiolitis. Exp Ther Med. 1:873–877. 2010.PubMed/NCBI
23	Zhou J, Xu XZ, Hu YR, Hu AR, Zhu CL and Gao GS: Cryptotanshinone induces inhibition of breast tumor growth by cytotoxic CD4⁺ T cells through the JAK2/STAT4/perforin pathway. Asian Pac J Cancer Prev. 15:2439–2445. 2014. View Article : Google Scholar : PubMed/NCBI
24	Hu Y, Hong Y, Xu Y, Liu P, Guo DH and Chen Y: Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis. 19:1627–1636. 2014. View Article : Google Scholar : PubMed/NCBI
25	Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S and Sozen S: Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro. Oncol Lett. 7:755–763. 2014.PubMed/NCBI
26	Jo SK, Hong JY, Park HJ and Lee SK: Anticancer activity of novel Daphnane Diterpenoids from Daphne genkwa through cell-cycle arrest and suppression of Akt/STAT/Src signalings in human lung cancer cells. Biomol Ther (Seoul). 20:513–519. 2012. View Article : Google Scholar : PubMed/NCBI
27	Sun W, Ma Y, Chen P and Wang D: MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-β/Smad2/STAT3/STAT5 pathway. Mol Med Rep. 11:3854–3859. 2015.PubMed/NCBI
28	Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn EJ, Yun M and Kim SH: Apoptosis induced by tanshinone IIa and cryptotanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2 signaling in chronic myeloid leukemia K562 cells. Evid Based Complement Alternat Med. 2013:8056392013. View Article : Google Scholar : PubMed/NCBI
29	Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC and Kwon BM: Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 69:193–202. 2009. View Article : Google Scholar : PubMed/NCBI